Matteo Siano Selected Research

Weight Gain

1/2021

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matteo Siano Research Topics

Disease

2	COVID-19 01/2021 - 01/2020
1	Weight Gain 01/2021
1	Neuroinflammatory Diseases 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2021
1	Obesity 01/2020
1	Non-alcoholic Fatty Liver Disease 11/2018
1	Fatty Liver 11/2018
1	Alcoholic Fatty Liver 11/2018
1	Inflammation (Inflammations) 11/2018

Drug/Important Bio-Agent (IBA)

1	Toll-Like Receptor 7IBA 01/2021
1	PK 11195 (PK11195)IBA 01/2021
1	2- (6- chloro- 2- (4- (3- fluoropropoxy)phenyl)imidazo(1,2- a)pyridin- 3- yl)- N,N- diethylacetamideIBA 01/2021
1	dolutegravirIBA 01/2021
1	Kainic Acid (Kainate)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	C-Reactive ProteinIBA 01/2020
1	CreatinineIBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Darunavir (Prezista)FDA Link 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 11/2018
1	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2018

Therapy/Procedure

1	Therapeutics 01/2021